Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

282

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
Schizophrenia
Interventions
DRUG

Talnetant

talnetant

OTHER

placebo

Placebo Comparator

OTHER

risperidone

Active Comparator

Trial Locations (22)

19131

GSK Investigational Site, Philadelphia

20016

GSK Investigational Site, Washington D.C.

23294

GSK Investigational Site, Richmond

30308

GSK Investigational Site, Atlanta

33161

GSK Investigational Site, North Miami

60523

GSK Investigational Site, Oak Brook

63118

GSK Investigational Site, St Louis

72201

GSK Investigational Site, Little Rock

75062

GSK Investigational Site, Irving

78756

GSK Investigational Site, Austin

90660

GSK Investigational Site, Pico Rivera

90703

GSK Investigational Site, Cerritos

91206

GSK Investigational Site, Glendale

91770

GSK Investigational Site, Rosemead

91786

GSK Investigational Site, Upland

91950

GSK Investigational Site, National City

92056

GSK Investigational Site, Oceanside

92123

GSK Investigational Site, San Diego

92126

GSK Investigational Site, San Diego

92805

GSK Investigational Site, Anaheim

92845

GSK Investigational Site, Garden Grove

08021

GSK Investigational Site, Clementon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY